biotech / news / / The Manila Times
Wegovy is a semaglutide 2.4 mg once-weekly injectable medication.
Novo Nordisk has officially launched prescription-only Wegovy for obesity management in the Philippines.
KEY POINTS
- Wegovy contains a higher dose of semaglutide than Ozempic, specifically for obesity treatment.
- The economic cost of obesity in the Philippines is projected to reach P1.9 trillion by 2025.
- Wegovy's benefits include improved cardiometabolic health beyond just weight loss and appetite regulation.
- Wegovy will be available in Philippine drugstores but strictly requires a doctor's prescription.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →